A B S T R A C T Monovalent goat antibody fragments (Fab) that were monospecific for human fibrinogen were isolated by affinity chromatography on fibrinogenSepharose and used as a direct probe for the involvement of fibrinogen in platelet aggregation and the release reaction. The antifibrinogen Fab inhibited aggregation of washed human platelets induced by thrombin (0.1-10 U/ml) by 50-95%, but had no effect on ["C]-serotonin release and only a slight inhibitory effect on "I-thrombin binding to platelets. Inhibition of aggregation was not observed with nonimmune goat Fab or rabbit antihuman albumin Fab. About 40,000 "2I-labeled antifibrinogen Fab molecules per platelet were bound tightly at saturation to surface fibrinogen molecules. After washing the platelets once to remove unbound Fab, aggregation by subsequently added thrombin was no longer inhibited. The antifibrinogen Fab inhibited the clotting of fibrinogen by thrombin but did not affect the rate of fibrinopeptide A release, indicating that the Fab inhibits clotting by interfering with the polymerization of fibrin monomers. Our experiments suggest that fibrinogen released from platelets is directly involved in thrombin-induced aggregation of washed platelets, perhaps through polymerization of fibrin monomers generated by proteolytic cleavage of released fibrinogen.
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INTRODUCTION
Thrombin initiates a series of rapid events in suspensions of washed human platelets. Within seconds after exposure to thrombin, platelets secrete calcium, sero-A preliminary report of this work was presented at the 17th Annual Meeting of the American Society of Hematology, Atlanta, Ga., 9 December 1974.
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Received for publication 3 December 1974 and in revised form 10 February 1975. tonin, adenine nucleotides, and other substances (a process termed the "release reaction", reference 1), and undergo a change in shape from flattened disks to spheres with many pseudopods (2) . Aggregation of the platelets occurs somewhat more slowly but is complete within several minutes. Thrombin induces these reactions at low concentrations of 1 nMI (0.1 U/ml) or less, suggesting that thrombin may be an important mediator of platelet function in hemostasis and thrombosis (3) .
Recently, several aspects of the mechanism by which thrombin initiates these events have been elucidated. Thrombin binds reversibly and with high affinity to about 50,000 receptors on the platelet surface (4) , which suggests that the plasma membrane is the prinmary site of action of thrombin. Thrombin treatment of intact platelets causes a rapid decrease in adenylate cyclase activity (5) and a concomitant increase in phosphorylation of a specific protein of molecular weight 40,000 (6) . Agents that presumably raise the intracellular concentration of cyclic adenosine 3',5'-monophosphate inhibit both the phosphorylation induced by thrombin and the release reaction (6, 7) , suggesting a possible relationship between these processes. A number of alterations in membrane components after thrombin treatment are indicated by changes in the pattern of proteins iodinated with lactoperoxidase (8) and in the number and distribution of lectin-binding sites (9, 10) , but the importance of these phenomena in aggregation and release is unclear. Thrombin inactivated with diisopropyl fluorophosphate is unable to induce release or aggregation (11) even though this rum, and plasma vs. goat antihuman fibrinog Antiserum was placed in the longitudinal electrophoresis, and the precipitates were all overnight at room temperature. bonds susceptible to hydrolysis by throm these has been shown to be hydrolyzed in lets during release or aggregation.
Several investigators have proposed fibrinogen is the substrate for thrombin an merizing fibrin" plays a central role in (15) (16) (17) , but evidence to the contrary h;
reported (11, (18) (19) (20) . In addition, nume tories have shown that added fibrinogen is ADP-induced aggregation but not for thro aggregation (21) (22) (23) serotonin before washing, and serotonin release was meaPlasma sured as described previously (4) .
Preparation of human fibrinogen-Sepharose. Sepharose 4B (100 ml settled volume) was activated by the procedure of Cuatrecasas (26) Measuiremient of antifibrinogen Fab binding to platelets. Fab fragments were iodinated, and binding studies were carried out as described previously for phlytohemagglutinin (28) .
Platelet aggregation studies. Aggregation was measured photometrically by the method of Born (29) in a Payton dual-channel aggregometer. Platelet suspensions (0.45 ml; 5 X 108 platelets/ml in isotonic Tris-saline containing 2 mM CaCI2) were warmed to 37'C in siliconized 'glass cuvettes and stirred at 1,100 rpm in the aggregometer. Additional substances were added totaling 0.05 ml. The recorder was adjusted to read 0% with a cuvette containing the starting platelet suspension and 100% with a cuvette containing buffer only.
Mcasurenietd of thrombin bindinbg to platelets. Bovine thrombin was labeled with 125I, and binding studies were carried out as described in a previous report (4) . "Nonspecific" binding of "2I-thrombin, which represented less than 25% of the total thrombin bound, was determined in incubations containing an excess of unlabeled thrombin and was a linear function of the "I-thrombin concentration. Binding data are presented in Fig. 5 after subtraction of nonspecific binding.
Mcasuiremeint of fibrinopeptides. Fibrinogen was dis-
solved in water and chromatographed on Sephadex G-150 equilibrated with 0.154 M sodium chloride, 0.01 M imidazole-HCI (pH 7.0). This procedure removed low molecular weight material that contributed to the fluorescence background of the assay. Reaction mixtures contained 150 pg/ml of fibrinogen, 0.02 M calcium chloride, and 1 U/ml of thrombin (added last to initiate the reaction) in 0.5 ml of the above buffer. The reaction was allowed to proceed at room temperature and was terminated by the addition of 0.05 ml of 100% trichloroacetic acid (TCA). The mixture was placed on ice, and the precipitate that formed was removed by centrifugation. An aliquot of the supernate (0.45 ml) was mixed with an equal volume of 0.4 M sodium phosphate (pH 8) containing 0.556 M sodium hydroxide to neutralize the TCA. Calcium phosphate precipitated and was removed by centrifugation. A 0.8-ml aliquot of the supernate, which contained the fibrinopeptides, was mixed rapidly with 0.2 ml of fluorescamine (3 mg/ml in acetone) on a Vortex mixer at room temperature (Scientific Industries, Inc., Queens Village, N. Y.) (30) . Relative fluorescence was measured in a Farrand A-4 fluorometer (Farrand Optical Co., Inc., Valhalla, N. Y.). The blank was a sample processed in an identical manner except that thrombin was omitted from the reaction.
To establish that fibrinopeptide A was measured by this procedure, a portion of the TCA supernate from a 2-min incubation with thrombin was subjected to paper electrophoresis as described by Herzig, Ratnoff, and Shainoff (31) . Duplicate electropherograms were stained for arginine (32) and for amino groups (by dipping the paper in 3 mg/ml fluorescamine in acetone). A single spot migrating as fibrinopeptide A was detected by both stains.
RESULTS
Purification of antihunan fibrinogen antibody. To test the effects of antibodies to fibrinogen on the reaction of thrombin with platelets, it was necessary to separate the antibodies from serum proteins that inhibit thrombin. Goat antiserum (45 ml) was chromatographed on a column of human fibrinogen-Sepharose as described in Methods (Fig. 2) . The affinity column was eluted first with 0.1 M sodium carbonate (pH 9.7). This eluate contained 39.7 mg of protein, and after dialysis against isotonic Tris-saline (pH 7.5), it precipitated 0. ELUTION VOLUME (ml) FIGURE 2 Affinity chromatography of goat antifibrinogen antiserum. Antiserum (45 ml) was treated with diisopropyl fluorophosphate as described in Methods and applied to a 95-ml column of human fibrinogen-Sepharose equilibrated with isotonic Tris-saline (pH 7.5). The column was washed with this buffer and eluted as shown. ELUTION VOLUME (ml) FIGURE (33) . Fibrino- gen located on the exterior surface of washed platelets would constitute a potential substrate in the initial thrombin-platelet interaction. In preliminary experiments using the isolated antifibrinogen antibodies labeled with "I, we determined that the antibodies bound to intact platelets, indicating the presence of platelet surface fibrinogen. Furthermore, these antibodies caused a slow release of ["C]serotonin from platelets at concentrations greater than 250 Ag/ml, which was consistent with previous experiments indicating that antibodies to platelet surface antigens stimulate release (34) . In an attempt to produce a probe for fibrinogen that would not stimulate release, we prepared monovalent Fab fragments from the purified antifibrinogen antibody by papain digestion, and the Fab fragments were isolated from the reaction mixture by affinity chromatography on fibrinogen-Sepharose (see Methods). In contrast to the intact antibody, the Fab fragments no longer induced the release reaction. The protein eluted from fibrinogen-Sepharose was identified as antihuman fibrinogen Fab fragments by the following criteria: (a) The protein had a molecular weight of 48,000 determined by Sephadex G-150 chromatography (Fig. 3) relative to standard proteins (35) . (b) The protein was bound completely to fibrinogen-Sepharose but no longer precipitated fibrinogen, although as seen in Fig. 3, Fig. 4 inset) (Fig. 5  inset) . From the experiment described above (Fig. 4) , we observed that approximately 40,000 antifibrinogen Fab molecules were bound per platelet at saturation with an apparent dissociation constant of 25 Ag/ml (determined from the intercept on the abscissa of (37) , the aggregometer is relatively insensitive to the formation of small aggregates (up to about 10 platelets each). To determine whether aggregates of this size were forming in the presence of the Fab, platelets were removed from the aggregometer cuvette and examined by phase-contrast microscopy in a hemocytometer. No aggregates were observed among platelets taken from the experiment n thrombin-induced shown in Fig. 8B (after 15 Control experiments were done to establish the specier by a negative ficity of the inhibition produced by the antifibrinogen or sites of a single Fab. Nonimmune goat Fab fragments had no effect on ith different affini-aggregation at protein concentrations greater than that thrombin binding required to produce complete inhibition by the antithrombin concen-fibrinogen Fab. Similarly, antihuman albumin Fab of thrombin-bind-from rabbits had no effect (Fig. 8C) (9) ; however, exogenous fibrinogen was not required for this reaction in washed platelets, and antifibrinogen Fab did not block this agglutination reaction (data not shown).
Platelet aggregation after preincubation with antifibrinogeni Fab. The above experiments suggested that fibrinogen is required for platelet aggregation but did not distinguish whether the effect of antifibrinogen Fab was on surface fibrinogen or on fibrinogen released from platelet granules. The following experiment was carried out to distinguish between these two possibilities. Platelets (5 X 109 in 10 ml of isotonic Tris-saline) were incubated for 10 min at room temperature with 1 mg of antifibrinogen Fab. The platelets were then centrifuged at 2,250 g for 15 min to remove unbound Fab fragments, resuspended in isotonic Tris-saline, and used in the aggregation experiment described in Fig.  9 . There was no apparent difference in thrombin-in- T ME (min) FIGURE 9 Effect of preincubation of platelets with antifibrinogen Fab on platelet aggregation. Platelets were incubated with Fab fragments and washed once as described in the text, and they were then resuspended at a concentration of 5 X 108 platelets/ml in isotonic Tris-saline (pH 7.5) contained glucose (1 mg/ml) and 2 mM calcium chloride. Thrombin (final concentration 1.0 U/ml) was added at the arrow. A, preincubated and washed platelets. B, preincubated and washed platelets + 100 ug/ml antifibrinogen Fab added 5 min before thrombin. Effect of antifibrinogen Fab on fibrinogen clotting and fibrinopeptide release. We studied the effect of the antifibrinogen Fab on clotting of fibrinogen by thrombin to determine how the Fab might affect the functional properties of fibrinogen. Antifibrinogen Fab fragments prolonged the clotting time of human fibrinogen exposed to thrombin, while Fab fragments prepared from nonimmune goat IgG had no effect (Table I ). The prolongation of clotting time could have resulted either from interference with the proteolytic conversion of fibrinogen to fibrin monomers (resulting in the release of fibrinopeptides A and B) or from interference with the polymerization of fibrin monomers to form a visible clot. As shown in Fig. 10 , the kinetics of fibrinopeptide release were identical in incubations with or without the antifibrinogen Fab. Since the peptides were quantitated with fluorescamine, a reagent that reacts with primary amino groups (30) , only fibrinopeptide A was detected in this experiment. Since others have found that removal of fibrinopeptide A alone is sufficient to cause clotting (38) . we infer that the anti- FIGURE 10 Effect of antifibrinogen Fab fragments on the release of fibrinopeptide A from human fibrinogen. Incubations containing 150 ,ug/ml of fibrinogen and 1 U/ml of thrombin were conducted as in the experiment in Table I Haslam has proposed that thrombin-induced aggregation depends on the release of ADP from the platelets, since an enzyme system capable of removing ADP from the incubation medium inhibits aggregation (39) .
It is well established that ADP and serotonin are released together from platelets under a variety of stimuli (1), and we can assume, therefore, that ADP release is not affected by the antifibrinogen Fab. It follows that released ADP cannot be the sole mediator of thrombin-induced aggregation.
Platelet fibrinogen comprises about 10% of the total protein content of platelets (33) . It cross-reacts immunologically with plasma fibrinogen, and although there is disagreement as to the structural identity of platelet and plasma fibrinogens (12, 40) , recent evidence would suggest that they are probably structurally identical (40) . Fibrinogen can be detected both on the surface of intact platelets (Fig. 4) and in platelet granules (33) from which the fibrinogen is released along with other granular constituents during the release reaction induced by thrombin (1). When platelets are preincubated with antifibrinogen Fab at a level sufficient to saturate the surface fibrinogen molecules and are then washed once to remove unbound Fab, we observe no inhibition of aggregation induced by subsequently added thrombin (Fig. 9) . This finding suggests that the Fab inhibits aggregation by binding to the fibrinogen released from platelets and that surface fibrinogen is unable to sustain aggregation of washed platelets.
We have shown that the antifibrinogen Fab preparation used in these experiments inhibits the clotting of fibrinogen by thrombin (Table I) , and since the rate of proteolytic cleavage of fibrinogen to release fibrinopeptide A is unaffected by the Fab (Fig. 10) , we infer that the Fab binds to fibrin monomers and interferes with their polymerization. The antifibrinogen Fab could thus inhibit platelet aggregation by inhibiting the polymerization of fibrin monomers generated from platelet fibrinogen. This suggestion should be regarded as tentative, however, until it can be shown that fibrin monomers are actually formed during aggregation. Alternatively, the Fab might prevent some function of the intact fibrinogen molecule, such as polymerization with itself or with fibrin monomers, which is essential for aggregation of the platelets. A role for fibrin monomer polymerization has been suggested also by Ardlie and Han (17) and by Niewiarowski, Regoeczi, Stewart, Senyi, and Mustard (16) . These investigators have reported that under certain conditions the addition of polymerizing fibrin to platelets causes aggregation, although various other cells, including leukocytes and fibroblasts, are also clumped under similar conditions (41) .
A small fraction of platelet fibrinogen is located on the platelet surface (see Results and Fig. 4) , where it might take part in the initial interaction of thrombin with platelets. Antifibrinogen Fab fragments at a level sufficient to saturate the surface fibrinogen molecules have no effect on ['4C]serotonin release (Figs. 6 and 7) and only slightly inhibit "low affinity" binding of "I-thrombin (Fig. 5) . These (11, 18, 19) .
In summary, our data suggest a direct involvement of released platelet fibrinogen in thrombin-induced aggregation of human platelets and are consistent with a model for platelet aggregation wherein polymerization of fibrin monomers serves to crosslink platelets into an aggregated mass. Thus "released" fibrinogen may be converted to fibrin monomers both in solution and on the platelet surface, and these monomers may then polymerize to form an aggregate. Whether the surface fibrinogen detected on resting platelets could participate in this process remains uncertain. These conclusions pertain only to the aggregation of washed platelets studied by the usual in vitro technique, which depends critically on temperature, stirring conditions, and other physical parameters. Certain clinical studies, however, suggest that platelet fibrinogen might also have an important function in vivo. For example, in a patient with Glanzmann's thrombasthenia who had a prolonged bleeding time, Zucker, Pert, and Hilgartner found reduced platelet fibrinogen even though the plasma fibrinogen level was normal (42) . This patient's platelets underwent a normal release reaction in vitro but did not aggregate in response to thrombin or other aggregating agents and thus resembled normal platelets inhibited, in our experiments, by antifibrinogen Fab fragments.
